| Authors: |
Evans TRJ; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. Thomas.Evans@glasgow.ac.uk., Cook N; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.; Division of Cancer Sciences, University of Manchester, Manchester, UK., El-Khoueiry A; Division of Medical Oncology, Keck School of Medicine, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Pinato DJ; Department of Surgery & Cancer, Imperial College London, London, UK.; Department of Translational Medicine, Division of Oncology, University of Piemonte Orientale, Novara, Italy., Tran NH; Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA., Hsiehchen D; Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX, USA., Mena E; Pasadena Liver Center, California Liver Research Institute, Pasadena, CA, USA., Meyer T; Research Department of Oncology, UCL Cancer Institute, University College London, London, UK.; Department of Oncology, Royal Free Hospital, London, UK., Wu J; Biostatics, Eisai Inc., Nutley, NJ, USA., Pathak SM; Clinical Pharmacology Science, Eisai Ltd, Hatfield, UK., Paoletti C; Clinical Research, Eisai Inc., Nutley, NJ, USA., Dutta L; Clinical Research, Eisai Inc., Nutley, NJ, USA., Okpara CE; Clinical Development, Eisai Ltd, Hatfield, UK., Lopez JS; Drug Development Unit, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, UK. |
